Majority of Americans Avoid Addressing End-of-Life Issues, According to New Study
San Diego, CA, December 10, 2013
Age, race, education level, and health status impact
Advance Directive Completion
Age, race, education level, and health status impact Advance Directive Completion
During the past two decades,
high-profile legal cases surrounding end-of-life decisions have received
widespread attention in the United States, prompting increased media focus and
numerous debates on the subject.
Despite this continuing nationwide dialogue, many Americans still tend to avoid addressing their own end-of-life (EOL) issues, including the completion of advance directives. In a new study published in the American Journal of Preventive Medicine, a group of investigators examined the factors associated with advance directive completion.
Although various national polls and selected state surveys provide some insight into American attitudes about advanced directives, there is a lack of population-based data regarding advance directive completion among adults. For this study, investigators analyzed data from the 2009 and 2010 Porter Novelli HealthStyles national surveys, which included EOL and advance directive-specific questions.
The team looked at responses from 7,946 participants in the HealthStyles survey and found that only 26.3% had completed an advance directive. The data showed that advance directives were more frequent among women, whites, respondents who had a college degree or postgraduate training, or were married. Respondents with advance directives also were more likely to report having a chronic disease and a regular source of care. The study shows significant associations between completing an advance directive and age, income, education, and health status.
"For black and Hispanic respondents, advance directives were less frequent across all educational groups. These data indicate racial and educational disparities in advance directive completion and highlight the need for education about their role in facilitating EOL decisions," explains Jaya K. Rao, MD, who, at the time the work was performed, was an Associate Professor in the Division of Pharmaceutical Outcomes and Policy at the Eshelman School of Pharmacy, University of North Carolina.
For respondents who had never completed an advance directive, investigators found that the most frequently reported reason for not having one was lack of awareness.
"The study provides information from a large sample of adults on their attitudes and behaviors regarding advance directives," says Lynda A. Anderson, PhD, Director, Healthy Aging Program, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. "Prior studies have focused on clinical populations, state samples, or certain age groups. People who lack the knowledge to have EOL concerns or discussions or about the role of advance directives in facilitating EOL decisions may represent potential targets for intervention."
While several investigations have shown that health care costs are greatest during the final years of life, researchers found that the use of advance directives was associated with lower levels of Medicare spending and a lower likelihood of in-hospital deaths.
"Given the current discussions about implementing various models of health care delivery, including the patient-centered medical home, EOL issues need to come to the forefront of planning efforts," adds Dr. Rao. "Hopefully, these findings will contribute to the current national conversations about EOL care."
# # #
Notes for editors
"Completion of Advance Directives Among U.S. Consumers," by Jaya K Rao, MD; Lynda A Anderson, PhD; Feng-Chang Lin, PhD; Jeffery P Laux, PhD, is published in the American Journal of Preventive Medicine, Volume 46, Issue 1 (January 2014), DOI http://dx.doi.org/10.1016/j.amepre.2013.09.008. It will be openly available.
Full text of the article is available to credentialed journalists upon request; contact Beverly Lytton at +1 858 534 9340 or eAJPM@ucsd.edu. Journalists wishing to interview the authors should contact Raines Behm at +1 404 639 3286 or email@example.com.
About the American Journal of Preventive Medicine
The American Journal of Preventive Medicine (www.ajpmonline.org) is the official journal of The American College of Preventive Medicine (www.acpm.org) and the Association for Prevention Teaching and Research (http://www.aptrweb.org/). It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials.
The American Journal of Preventive Medicine, with an Impact Factor of 3.945, is ranked 15th out of 158 Public, Environmental, and Occupational Health titles and 18th out of 151 General & Internal Medicine titles according to the 2012 Journal Citation Reports® published by Thomson Reuters.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 858 534 9340